Cartesian Therapeutics, Inc. (RNAC)
7.00
+0.22
(+3.24%)
USD |
NASDAQ |
Nov 06, 10:23
Cartesian Therapeutics Total Assets (Quarterly) : 318.63M for June 30, 2026
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 318.63M |
| March 31, 2026 | 288.39M |
| December 31, 2025 | 296.41M |
| September 30, 2025 | 372.68M |
| June 30, 2025 | 388.89M |
| March 31, 2025 | 409.13M |
| September 30, 2024 | 455.32M |
| June 30, 2024 | 347.74M |
| March 31, 2024 | 325.21M |
| December 31, 2023 | 305.05M |
| September 30, 2023 | 106.03M |
| June 30, 2023 | 139.51M |
| March 31, 2023 | 155.69M |
| December 31, 2022 | 165.89M |
| September 30, 2022 | 178.26M |
| June 30, 2022 | 188.07M |
| March 31, 2022 | 145.70M |
| December 31, 2021 | 159.88M |
| September 30, 2021 | 167.16M |
| June 30, 2021 | 180.52M |
| March 31, 2021 | 176.75M |
| Date | Value |
|---|---|
| December 31, 2020 | 165.44M |
| September 30, 2020 | 181.00M |
| June 30, 2020 | 75.21M |
| March 31, 2020 | 88.80M |
| December 31, 2019 | 99.57M |
| September 30, 2019 | 39.54M |
| June 30, 2019 | 46.95M |
| March 31, 2019 | 62.48M |
| December 31, 2018 | 44.48M |
| September 30, 2018 | 60.32M |
| June 30, 2018 | 73.44M |
| March 31, 2018 | 89.94M |
| December 31, 2017 | 101.10M |
| September 30, 2017 | 109.72M |
| June 30, 2017 | 117.02M |
| March 31, 2017 | 73.86M |
| December 31, 2016 | 89.30M |
| September 30, 2016 | 85.78M |
| June 30, 2016 | 91.32M |
| March 31, 2016 | 34.72M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.112B |
| Oncolytics Biotech, Inc. | 7.671M |
| Sangamo Therapeutics, Inc. | 59.96M |
| Sarepta Therapeutics, Inc. | 3.189B |
| Anixa Biosciences, Inc. | 15.07M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 443.85M |
| Shareholders Equity (Quarterly) | -125.23M |
| Debt to Equity Ratio | -0.5099 |
| Current Ratio | 7.475 |
| Net Debt Paydown Yield | -3.18% |